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Tmplantable Atrial Defibrillator. Introduction: The purpose of our study was lo evaluate
the ettect uf repeated cardioversiun with an implantable atrial defibrillator on tbe clinical
outcome of patients witb atrial fibrillation.
Methods and Results: Tbe effects of the implantable atrial defibrillator on the total duration
of atrial fibrillation, number of atriat Hbriliation recurrences, and left atrial size were evaluated
prospectively in 16 patients witb atrial fibrillation (13 men and 3 women; mean age 58 ± 11
years). Seven patients bad no cardiovascular disease, 5 patients had hypertension. 3 patients had
coronary beart disease, and 1 patient bad congenital heart disease. Eight patients had parox-
ysmal atrial fibrillation for a mean duration of 80 ± 61 montbs, and eigbt patients had persistent
atrial fihrillation for a mean duration of 68 ± 119 months. Except for one patient who received
digoxin throughout the study, alt patients received tbe same Class I or III antiarrbythmic agent
tbroughout tbe study. Tbe implantable atrial defibrillator successfully converted 50 (93%) of 54
spontaneous episodes of atrial fibrillation in 12 patients. During the initial 3 months of clinical
follow-up, the atrial defibrillator documented 261 ± 270 hours of atrial fibrillation compared
with 126 ± 172 bours (P = 0.01) during tbe subsequent 3 months. Tbe left atrial size decreased
from 4.4 ± 0.7 cm at tbe time of atrial defibrillator implantation to 4.1 ± 0.6 cm (P = 0.02) 6
montbs later. The number of atrial fibrillation recurrences did not cbange. Tbese findings were
observed in the absence of cbanges in drug tberapy. No complications were observed.
Conclusion: Restoration and maintenance of sinus rhythm in patients with atrial fibrillation by
repeated cardioversion witb an implantable atrial defibrillator was associated witb a reduction in the
total arrbytbmia duration and a reduction in left atrial size. Tbese results suggest that maintenance
of sinus rbytbm witb the atriai defibrillator may reverse tbe remodeling process associated witb
atrial fibrillation. (J Cardiovusc Elecirophysiol. VoL JO, pp. 1200-1209, Septetnber 1999)
cardioversion, supraventricular arrhythmia, atrial fibrillation
Introduction
Recent studies in animals and humans suggest
that atrial fibrillation alters tbe electrophysi-
ologic properties of the atrium and facilitates the
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maintenance and recurrence of atrial fibrilla-
tion.'-̂  If the electrophysiologic changes associ-
ated with atrial fibrillation can be prevented with
early cardioversion. the likelihood of recurrent
atrial fibrillation and its sequelae may be re-
duced. The implantable atrial defibrillator is an
effective device for the early detection and car-
dioversion of atrial fibrillation.'^ The purpose of
this study was to evaluate prospectively the ef-
fect of implantable atrial defibrillator tberapy on
the natural bistory of atrial tibrillaiion.
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A = amiodarone: AF = atrial fibrillation; ASA = aspirin; BB = beta blocker; CAD = coronary artery disease; CHD = congenital hean
disease; Dig = digoxin: D = diltiazem; F = fetnale; Fl = flecainide; HT = hypertension; LA = left atrium; LVEF = left ventricular ejection
fraction; M = male; P = propafenone; Q = quinidine; S = sotalol; W = warfarin.
Methods
Patient Popttlation
The study population consisted of 13 men and
3 women (mean age 58 ± I 1 years) who were
treated with an implantable atrial defibrillator for
symptomatic, drug-refractory atrial fibrillation
(Table 1). Seven patients had no cardiovascular
disease, 5 patients had hypertension. 3 patients
bad coronary beart disease, and I patient had
congenital heart disease. Eacb patient had recur-
rences of alrial fibrillation despite treatment with
at least one Class I or III antiarrhythmic drug.
During episodes of atrial fibrillation, 2 patients
noted dizziness, 11 noted palpitations. 5 noted
shortness of breath. 6 noted chest pain, and 11
noted weakness.
Prior to implantation of tbe atrial defibrilla-
tor. atrial fibrillation terminated spontaneously
within 48 bours of onset in eight patients with
paroxysmal atrial fibdllation. Atrial fibrillation
recurred at least 2 weeks after successful external
or internal cardioversion and persisted indefi-
nitely and for at least the 1 month prior to device
implantation in eigbt patients witb persistent
atrial fibrillation. The patients bad paroxysmal
atrial fibrillation for 80 ± 61 months (range 18 to
168), The eight patients had persistent atrial fi-
brillation for a mean duration of 68 -^i 119
months, and tbe most recent episode had per-
sisted for 3.9 ± 1.9 months (range 1 to 8), There
were no identifiable differences between patients
with paroxysmal and persistent atrial fibrillation
(Table 2),
After a detailed medical history and physical
examination, all patients underwent a preproce-
dure evaluation consisting of a 12-lead ECG.
24-hour Holter monitoring, chest radiograph,
transthoracic and transesophageal echocardiog-
Age (years)
Male/Fetiiale
Duration of atrial fihrillation (months)
Structural heart disease (%')
Left ventricular ejection fraction
Left atrial diatneter (cm)
TABLE 2

























Values are given as mean ± SD.
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Figure I. Posteroanterior che.st radiograph of a patient with a two-lead (A) and a three-lead (B) implantable atrial
defibrittator system. (A) The lead with mvi defitirillation coils was positioned in the right atrium and distal corotiary sinus. (B)
An active fixation lead with a single defihriltution coil was positioned in the right atrium and a pa.s.sive fixation lead with a
single defibrillation coil was positioned in the coronary sinus. Both sy,stems utilized a standard bipolar pacing lead for
ventricular sensitig ami pacing.
raphy. serum electrolyte measurements, com-
plete blood court, and thyroid function tests. Pa-
tients with any of the following conditions were
excluded from study participation: (I) reversible
causes of atrial Hbrillation. such as electrolyte
imbalance or hyperthyroidism; (2) clinically sig-
nificant valvular beart disease or the presence of
a cardiac valve prosthesis; (3) unstable angina or
a myocardial infarction within the previous 6
months; (4) New York Heart Association Class
III or IV heart failure during sinus rhythm;
(5) echocardiograpbic evidence of left atrial
thrombi; or (6) coexisting ventricular taehy-
anhythmias.
Implantable Atrial Defihrillator System
The ethics committee or institutional review
board at botb participating centers approved the
protocol. Written inft)rnicd consent was obtained
from each patient. A previously described im-
plantable atrial detibrillator (models 3000 or
3020, Guidant. St. Paul, MN. USA) was used in
conjunction with either a one- or two-lead defi-
brillation system.' "̂  Both lead systems were po-
sitioned under Muoroscopic guidance from the
cephalic and/or subclavian vein. In three pa-
tients, a single passive fixation defibrillation lead
was positioned in the coronary sinus (Fig. IA).
This lead had a distal defibrillation coil that was
positioned in the coronary sinus and a proximal
defibrillation coil that was positioned in tbe right
atrium {Guidant model 7309). In 13 patients, a
dual lead system was utilized (Fig. IB). An ac-
tive fixation lead with a single defibrillation coil
(Guidant model 7205) was ptisitioned in the right
atrium. Tbe second passive fixation lead that was
positioned in the coronary sinus also had a single
defibrillation coil (Guidant model 7109). A stan-
dard bipolar endocardia! ventricular pacing lead
was used for R wave synchronization and ven-
tricular pacing with each of tbe defibrillation lead
systems.
The implantable atrial defibrillator performed
atrial sensing and defibrillation between the right
atrial and coronary sinus coil electrodes. The
intracardiac atrial and ventricular electrograms
were used in specific algorithms for atrial fibril-
lation detection and R wave synchronization.^
The deviee stored the atrial and ventricular intra-
cardiac electrograms from the six most recently
identitied episodes of atrial fibrillation. Tbe
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stored data included how the device synchro-
nized to the ventricular electrogram. the date and
time of the onset of episodes of atrial fibrillation,
and the duration of tbe 170 most recently de-
tected atrial fibrillation episodes. Shocks were
synchronized to tbe ventricular electrogram and
were only delivered after an RR interval of at
least 500 msec. VVI pacing was a programmable
feature.
Although the implantable atrial defibrillator
had three programmable therapy modes, only the
monitor mode was used when patients were out-
side the hospital. The device was programmed to
sense every 120 minutes. When the sensing se-
quence was initiated, atrial electrogram sensing
and R wave synchronization were performed.
Tbe sensing interval required approximately 2
minutes to complete, then the cycle was re-
peated. In the monitor mode, the device stored
episode data, but did not deliver shocks. Patients
were instructed to come to the hospital or clinic
for each episode of symptomatic atrial fibrilla-
tion. Under physician supervision, the device
was programmed to the automatic mode, and a
shock was automatically delivered. Sedation
with intravenous midazolam was administered at
the request of the patient. Success or failure of
each shock was noted. Early reinitiation of atrial
fibrillation was defined as the recurrence of atrial
fibrillation within I minute of a successful car-
dioversion."" The implantable atrial defibrillator
delivered a biphasie shock with a leading- and
trailing-edge duration of either 3 or 6 msec, with
a maximum output of 300 V (Guidant models
3000 and 3020).
Atrial Defibrillation Threshold Testing
The atrial defibrillation threshold was deter-
mined using an up-down defibrillation protocol
starting at 180 V after adequate sedation was
achieved with intiavenous fentanyl and/or mida-
zolam."̂  Implantation of the device required suc-
cessful conversion of atrial fibrillation to sinus
rhythm with at least 1 of 3 attempts using either
260 V (Guidant model 3000) or 240 V (Guidant
model 3020). Atrial defibrillation threshold test-
ing was repeated using the same protocol I and 3
months after device implantation. When patients
were in sinus rhythm, atrial fibrillation was in-
duced with a low-intensity shock synchronized
to the R wave or with rapid atrial pacing through
a temporary catheter.
Implantahle Atrial Defibrillator Episode Log
The device's episode log was used to identify
the duration of each episode of atrial fibrillation
with an accuracy of ± 2 hours. An episode ol
atrial fibrillation identified during only one sens-
ing interval was defined as persisting for 2 bours,
but actually may have persisted from I minute to
3 hours 59 minutes. The longest single episode of
atrial fibrillation that could be recorded with this
device was 340 hours. If 170 consecutive sensing
intervals demonstrated atrial fibrillation, tben tbe
episode was defined as lasting 340 hours. How-
ever, tbis observation could have been due to
paroxysmal episodes of atrial fibrillation that
were present during eacb sensing interval. Addi-
tionally, in this instance, the epi.stide may bave
persisted beyond 340 hours.
EoUow-Up
An investigator evaluated each patient 1, 3,
and 6 months after the implantable atrial defibril-
lator was implanted, f^uritig these outpatient vis-
its, the device was interrogated to determine the
number and total duration of atrial hbriliation
episodes. A surface echocardiogram was per-
formed during the 6-month follow-up visit lo
evaluate the left atrial diameter and left ventric-
ular ejection fraction. Lelt atrial size from the
baseline and follow-up surface echocaidiograms
was estimated from the parasternal long-axis
view. The measurement was determined inde-
pendently by two echocardiographers in a subset
of 1 1 patients. The measurements obtained from
each echocardiogram were within I nun in each
case. From the time of atrial defibrillator implan-
tation and throughout the study pcritid. the goal
was to avoid altering antiarrhytbmic drug ther-
apy, if possible. Aspirin or warfarin was pre-
scribed at the discretion of tbe investigator (Ta-
ble 1).
Antiarrbythmic medication remained un-
changed throughout the study perit)d (Table 1).
However, the dosage was adjusted in six patients
who were receiving amiodarone. The dosage of
amiodarone was reduced in one patient who de-
veloped symptomatic bradycardia and in two pa-
tients in whom spontaneous episodes of atrial
fibrillation could not be converted with 300 V. In
the remaining three patients, tbe dosage of ami-
odarone was temporarily increased for 2 weeks
because of two or more symptomatic episodes of
atrial fibrillation per week. After atrial defibril-
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lator implantation, 12 patients were treated with
warfarin and 2 patients were treated with aspirin
(Table I).
Statistical Analysis
Continuous variables are expressed as mean ±
1 SD and were compared using a /-test or an
analysis of variance, as appropriate. Discrete
variables were compared using a Chi-square test.
A prospective decision was made to evaluate the
data from all patients and to stratify the data
according to the diagnosis of persistent or par-
oxysmal atrial fibrillation. Additionally, a pro-
spective decision was made to compare the num-
ber of episodes of atrial fibrillation and total
duration of atrial fibrillation that occurred during
the first 3 months and second 3 months after the
atrial defibriliator was implanted. P < 0.05 was
considered statistically significant.
54 spontaneous episodes of atrial fibrillation
(2.7 ± 2.1 shocks per episode; range 1 to II).
Shock therapy from the iniptantable atrial defi-
briliator terminated 50 (93%) of 54 of these
episodes, with 2.4 ± 1.9 shocks per atrial (ihril-
lation episode (range 1 to 11). A single implant-
able atrial defibriliator shock terminated and re-
stored sinus rhythm during 12 (22'^ ) of the
spontaneous episodes of atrial tibrillation.
Four patients had an episode of atrial Hbrilla-
tion that did not convert to sinus rhythm after
4.5 ± 2.4 shocks (range 3 to 8). Two of these
four episodes spontaneously converted to sinus
rhythm 1 and 2 days later. In the other two
patients, the dosage of amiodarone was reduced
and sinus rhythm was restored by the implant-
able atrial defibriliator with two shocks in each
patient 2 weeks later. Three patients developed
symptomatic bradycardia after shock therapy and
required temporary VVI pacing from the device.
Results
Treatment of Spontaneous Episodes of Atrial
Fibrillation
During the 6-month follow-up. 12 patients
(75%) received implantable atrial defibriliator
therapy for at least one spontaneous episode of
atrial fibrillation, and 4 patients did not receive
implantable atrial defibriliator therapy for a
spontaneous episode ot atrial fibrillation. In I of
the 4 patients who did not receive a shock from
the implantable atrial defibriliator for a sponta-
neous episode of atrial fibrillation, atrial fibrilla-
tion did not recur after the implantable atrial
defibriliator was implanted for the treatment of
persistent atrial fibrillation. The remaining three
patients who had a history of paroxysmal atrial
fibrillation developed symptomatic atrial fibrilla-
tion, but they did nt)t come to the hospital for
cardioversion hy the implantable atrial defibril-
iator.
The 12 patients who received implantable
atrial defibriliator therapy had 54 episodes of
spontaneous atrial fibrillation for which a shock
frotn the device was delivered (4.5 ± 4,1 epi-
sodes per patient; range 1 to 14). Seventeen of
these episodes (31%) occurred in five patients
with paroxysmal atrial fibrillation. The remain-
ing 37 episodes (69%) occurred in seven patients
with persistent atrial fibrillation. A total of 136
shocks were delivered for the treatment of these
Arrhythmia Recurrences
In the first 3 months after atrial defibriliator
implantation, the number of spontaneous epi-
sodes of atrial fibrillation per patient (15 ± 16)
was the same as during the subsequent 3 months
of follow-up (12 ± 16; P = 0.2). However, the
total duration of atrial fibrillation decreased from
126 ± 172 hours during ihc second 3 months
compared with 261 ± 270 hours during the ini-
tial 3 months CP = 0.01), after atrial defibriliator
implantation (Fig. 2).
There was no significant difference in the
number of spontaneous atrial fibrillation epi-
sodes between patients with paroxystnal and per-
sistent atrial fibrillation during the initial 3
months (22 ± 18 episodes per patient vs 9 ± 13
episodes per patient; P = 0.2) and subsequent 3
months (20 ± 20 episodes per patient vs 5 ± 5
episodes per patient; P = 0.08) after atrial defi-
briliator implantation. During the initial 3
months after device implantation, the total dura-
tion of atrial fibrillation for patients with parox-
ystnal atrial librillation was 135 ± 98 hours
compared with 391 ± 330 hours for patients with
persistent atrial fibrillation (P < 0.05). During
the second 3 months alter itnplantabic atrial de-
fibriliator implantation, the total duration of atrial
fibrillation was not significantly different be-
tween patients with paroxystnal (68 ± 120
hours) and persistent alrial fibrillation (185 ±
204 hours; P = 0.2; Fig. 2). Subgroup analysis
demonstrated that the total duration of atrial fi-
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Figure 2. Total duration of atrial fibrillation (AF}for each
patient during the first and second 3-month periods after the
atriai defibrillator was implanted. Statistically significant p
values are shown. Circles represent the mean duration (±
} SD) of AF in all of the patients. Triangles and squares
represent the mean (± I SD) and individual data for pa-
tients with persistent and paroxysmal atrial fibrillation,
respectively.
brillation did not change significantly among pa-
tients with paroxysmal atria! fibrillation (36 ± 98
hours vs 68 ± 120 hours; P = 0.09), whereas
patients with persistent atrial fibrillation bad a
significant reduction in the total duration of atrial
fibrillation (391 ± 330 hours vs 185 ± 204
hours; P < 0.05). Six months after implantable
atrial defibrillator implantation, eacb patient was
in sinus rhythm.
Echocardiographic Results
At the time of atrial defibrillator implantation,
the mean left ventricular ejection fraction was
0.56 ± 0.08, and the mean left atrial diameter by
eehocardiography was 4.4 ± 0.7 cm. Prior to
implantation of the device, patients with persis-
tent atrial fibrillation had a significantly larger
left atrial diameter than patients with paroxysmal
atrial fibrillation (4.8 ± 0,8 cm vs 4,1 ± 0.5 cm;
P = 0.03; Table 2). After 6 months of treatment
with the implantable atrial defibrillator, left ven-
tricular ejection fraction did not change signifi-
cantly (0.59 ± 0.05; P = 0.08); however, there
was a significant reduction in left atrial size com-
pared with before device implantation (4,1 ± 0.6
cm; P = 0.02; Fig. 3). Left atrial size did not
change significantly among patients with parox-
ysmal atrial fibrillation (4.1 ± 0.5 cm vs 4.0 ±
0.4 cm; P = 0.2), whereas patients with persis-
tent atrial fibrillation demonstrated a significant
reduction in left atrial size (4.8 ± 0.8 cm vs
4.3 ± 0.7 cm; P < 0.05; Fig. 3).
Early Reinitiation of Atrial Fibrillation
Reinitiation of atrial fibrillation within 1
minute of successful cardioversion of a sponta-
neous episode of atrial tibrillation occurred after
11 (20%) of 54 successfully treated episodes of
atrial fibrillation in 6 of the 12 patients who
received treatment for a spontaneous episode of
atrial fibrillation. If early reinitiation of atrial
fibrillation is considered a clinical failure, then
the overall clinical efficacy ol' the device was
83%. Sinus rhythm was restored after six of these
episodes with acute administration of intrave-
nous procainamide in I patient, intravenous He-
cainide in 2 patients, and intravenous sotalol in 3
patients, followed immediately by cardioversitin
with the device. In tbe remaining five episodes, I
patient converted spontaneously to sinus rhythm
20 minutes after intravenous adtninJstration of
flecainide and 4 patients converted spontane-
ously to sinus rhythm without further therapy
within 48 hours. Implantable atrial defibrillator
tberapy associated witb early reinitiation of atrial












Figure 3. Left atriat diameter determined by eehocardiog-
raphy at the time of implantable atrial defibrillator implan-
tation and 6 motiths later for each patient. Statistically
significant p values are shown. Symbols as in Figure 2.
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Implant 1 month 3 montbs
Implant 1 month 3 months
Figure 4. Atriat defibriltation ttirestwtd (ADFT) in volts (V)
and joules (J) determined during device implantation, and 1
and 3 months later. Soltd bars tnctude all patients: open
bars include only data from patients with paroxysmal atriat
fibrittation; and luuched bars include onty data from pa-
tients with persistent atriat fibrillation. Statistically signifi-
cant p values are shown.
tibrillation episode compared with 2.2 ± 1.5
shocks per atrial fibrillation episode that was not
associated with early reinitiation of atrial fibril-
lation (P = 0.02).
Atrial Defihrillation Thresholds
The mean atrial dclibrillalion thresholds were
250 ± 36 V (3.5 ± 1,3 J), 270 ± 45 V (4.3 ± 1.0
J). and 245 ± 56 V (3.6 ± 1.8 J) at implant, I
month, and 3 months after device implantation,
respectively (P ~ 0.6; Fig. 4). The mean lead
impedance was 65 ± 4 H at implant and did not
change during follow-up (P = 0.8). There was no
significant difference in the initial atrial delibril-
lation threshold between patients receiving or not
receiving amiodarone (255 ± 10 V vs 240 ± 15
V; P — 0.5). At implant, three patients witb
persistent atrial fibrillation bad an atrial defibril-
lation threshold > 260 V. After tbe administra-
tion of intravenous ibutilide in two patients and
intravenous sotalol in one patient, an atrial defi-
brillation tbresbold < 260 V was achieved.
During device implantation, the atrial detibril-
lation threshold was significantly greater in pa-
tients witb persistent atrial fibrillation (272 ± 18
V; 4.6 ± 0.8 J) than in patients with paroxysmal
atrial tibrillation (228 ± 35 V, P < 0.01; 2.5 ±
1 J, P < 0.001; Fig. 4). There was no significant
difference in the atrial detibrillation threshold
between patients with paroxysmal and persistent
atrial fibrillation during tbe 1-month {248 ± 60
V vs 276 ± 18 V; P = 0.2) and 3-montb (240 ±
61 V vs 250 ± 53 V; P = 0.7) atrial defibrillation
threshold determination. The shocking imped-
ance was similar between these two groups of
patients during tbe initial and subsequent atrial
defibrillation tbreshold determinations (P = 0.8).
The atrial detibrillation threshold was signiti-
cantly greater among patients witb persistent, as
compared with paroxysmal, atrial fibriiiation
(P < 0.01; Table 2). Otherwise, there was no
significant correlation between the initial atrial
defibrillation threshold and any identitiable clin-
ical characteristic, including age (P = 0.7), gen-
der (P = 0.8), duration of atrial fibrillation (P =
0.5), left ventricular ejection fraction (P = 0.3),
or left atrial size (P = 0.3).
Tolerance of Shocks
Two (17%) of 12 patients did not request
sedation for implantable atrial detibrillator ther-
apy tbat was delivered for 17 spontaneous epi-
sodes of atrial fibrillation. Four patients tolerated
a single atrial defibrillator sbock witbout seda-
tion during six spontaneous episodes of atriai
fibrillation, but requested sedation when more
than one shock was required. The remaining six
patients requested sedation for 26 spontaneous
episodes of atrial fibrillation for wbicb atrial de-
fibrillator tberapy was delivered. Sedation was
acbieved witb intravenous administration of 2 to
10 mg of midazolam (5.3 ± 3.2 mg).
Complications
There were no acute complications associated
witb implantation of tbe atrial defibrillator. One
patient developed subclavian vein thrombosis 2
weeks after the device was implanted and was
treated with warfarin. Ventricular proarrhytbmia
was not observed during tbe study. No thrombo-
embolic events were noted during the study.
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Discussion
Main Findings
The major finding of this study is that main-
tenance of sinus rhytbm witb repeated cardiover-
sion with an implantable atrial defibrillator in
combination with antiarrhythmic drugs may fa-
vorably infiuence the natural bistory of atrial
fibrillation by reducing the total duration of atrial
tibrillation and reducing left atrial size in patients
witb persistent atrial fibrillation.
Mechanism
Although tbe technical feasibility, safety, and
efficacy of the implantable atrial detibrillator bas
been reported,^-'' tbe data contained berein are the
first to suggest that aggressive maintenance of
sinus rhytbm with tbe implantable atrial defibril-
lator may alter tbe progressive nature of atrial
tibrillation, may reverse at least some portion of
tbe associated atrial myopatby, and support the
notion that sinus rhythm predisposes to sinus
rbytbm.
Previous studies in animals and bumans sug-
gest tbat rapid cardioversion of atrial tibrillation
may prevent tbe electrical remodeling that occurs
with atrial fibrillation, tbat paroxysmal and per-
sistent atrial fibrillation lead to progressive atrial
enlargement, and that left atrial size correlates
with the duration of atrial fibrillation.'•-•^•'^ This
suggests that enlarged atria are more likely to
occur in patients witb persistent atrial fibrillation
and, therefore, would be more likely to demon-
strate reversal of this process with maintenance
of sinus rbytbm. Additionally, atrial enlargement
is associated witb a greater risk of arrhythmia
recurrence, as well as tbromboembolic compli-
cations.'"'- Tbe results of the present study im-
ply that restoration and maintenance of sinus
rhythm by repeated cardioversion may reverse
the process of left atrial enlargement by revers-
ing the mechanical remodeling process associ-
ated with atrial fibrillation. Tbe reduction in left
atrial size and total duration of atrial fibrillation
was more prominent in patients with persistent
atrial tibrillation than in those with paroxysmal
atrial fibrillation. The strength of these data is
limited by tbe relatively small sample size, only
two echocardiograpbic measurements of left
atrial size, and a clinical follow-up period of only
6 months. However, additional investigation is
required to determine if maintenance of sinus
rhythm and a reduction in left atrial size will
reduce the risk of the thromboembolic complica-
tions associated with atrial fibrillation.
Early Reinitiation of Atrial Fihrillation
Early reinitiation of atrial tibrillation occurs
after successful internal dofibrillation, with t)r
without an implantable atrial delibrillator, in
13% to 36% of patients.^'^-'^ A 20% incidence
was noted in the present study. Atrial fibrillation
is associated with atrial electrical remodeling in
animals and humans and is the mechanism
whereby atrial tihrillation provokes atrial fibril-
lation.'-^ It is reasonable to assume tbat electrical
remodeling also is responsible for early reinita-
tion of atrial fibrillation after a successtui cardio-
version. In tbe present study, early reinitiation of
atrial fibrillation was associated with an in-
creased luimber of shocks per atrial fihiillation
episode and a reduced overall clinical efticacy of
the implantable atrial defibrillator from 93% to
83%. In tbe present study and in previous re-
ports, intravenous administration of a Class I or
Til antiarrhytbmic agent appeared to suppress the
early reinitiation of atrial tibrillation in some
Concomitant Drug Therapy
Although the implantahle atrial detibrillator
effectively restored sinus rhythm, the majority of
patients still required chronic adjunctive antiar-
rhythmic therapy to reduce the frequency of
atrial fibrillation or to prevent early recurrences
of atrial tibrillation. Antiarrhytbmic agents also
may influence the efticacy of cardioversion witb
tbe implantable atrial defibriliator. In the present
study, tbere was no significant difference in tbe
initial atrial defibrillation threshold between pa-
tients undergoing concomitant treatment with or
witbout amiodarone. However, in two patients
wbo failed cardioversion, a reduction of the ami-
odarone dosage was associated with a reduction
of the atrial defibrillation requirement In previ-
ous studies, amiodarone bad a variable etfect on
the atrial detibrillation tbreshold, and intravenous
sotalol and ibutilide were associated with a lower
atrial defibrillation threshold."''^"
Patient Acceptance of Implantable Atrial
Defibrillator Therapy
For the implantable atrial defibrillator to be a
viable clinical tool, the discomfort associated
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with device shocks must be manageable. In the
present study, only 20% of patients underwent
atrial detibrillator sbocks without sedation. The
discomfort associated witb the shocks may be
related to the number of delivered shocks and not
to tbe intensity of tbe individual shocks.^' Tbere-
fore, to improve patient acceptance of the im-
plantable atrial defibrillator. the first shock en-
ergy should be associated with a high probability
of successful defibrillation. Successful defibrilla-
tion is a function of many factors, including
electrode design and position, shock waveform
and polarity, concomitant antiarrhythmic drug
therapy, and clinical factors.'^•*'^*' Maximizing
the defibrillation system may increase the num-
ber of patients who do not require sedation. Fi-
nally, the use of an oral sedative witb rapid
absorption and a short duration of action prior to
implantable atrial defibrillator tberapy may in-
crease patient acceptances^
Limitations
The major limitation of this study is that,
depending on when the atrial fibrillation episode
occurred relative to tbe sensing cycle, some ep-
isodes of atrial tibrillation may not have been
sensed while multiple episodes may have been
defined as a single episode. Due to this device
limitation, the duration and number of episodes
may bave been overcounted or undercounted.
However, overcounting and undercounting most
likely occurred randomly throughout the study,
thereby reducing or eliminating the importance
of this limitation. The second limitation of tbis
study is that the .serial echocardiograms and atrial
defiibrillation thresholds were not performed at
the same points in time. This limits the ability to
correlate tlie findings from these two tests. Fi-
nally, the natural history of persistent and parox-
ysmal atrial fibrillation is not well defined.
Clinical Implications
The results of the present study suggest that
repeated cardioversion with an implantable atrial
defibrillator might reverse tbe process of me-
chanical atrial remodeling in patients witb per-
sistent atrial fibrillation. The use of the implant-
able atrial defihrillator in tbe patient activated or
automatic mode may intensify this effect by pro-
viding prompter tberapy for atrial fibrillation.
The impiantable atrial defibritlator may have a
greater effect on the natural bistory of atrial
fibrillation in patients with persistent atria! fibril-
lation as opposed to patients with paroxysmal
atrial fibrillation.
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